Conservative management of < 3cm anterior mediastinal lesions in lung cancer screening is safe - Takeaways - MDSpire

Conservative management of < 3cm anterior mediastinal lesions in lung cancer screening is safe

  • By

  • Amyn Bhamani

  • Chuen R. Khaw

  • Ruth Prendecki

  • Priyam Verghese

  • Andrew Creamer

  • Jennifer L. Dickson

  • Carolyn Horst

  • Helen Hall

  • Sophie Tisi

  • Monica Mullin

  • Tanya Patrick

  • John McCabe

  • Anne-Marie Hacker

  • Laura Farrelly

  • Esther Arthur-Darkwa

  • Neal Navani

  • Anand Devaraj

  • Allan Hackshaw

  • Arjun Nair

  • Sam M. Janes

  • July 4, 2026

  • 0 min

Share

  • 1

    Low-dose computed tomography (LDCT) screening is being implemented in the UK to reduce lung cancer-related mortality by 2030.

  • 2

    Management protocols for incidental findings from LDCT screening aim to minimize over-diagnosis while ensuring timely interventions.

  • 3

    Anterior mediastinal lesions are infrequently encountered in lung cancer screening, with a prevalence of 0.4% to 0.9% in various studies.

  • 4

    In the SUMMIT Study, anterior mediastinal lesions < 3 cm were managed conservatively with annual follow-up LDCT imaging.

  • 5

    The study's primary objective was to assess the safety of conservative management for anterior mediastinal lesions under 3 cm.

Original Source(s)

Conservative management of < 3cm anterior mediastinal lesions in lung cancer screening is safe

  • by Amyn Bhamani, Chuen R. Khaw, Ruth Prendecki, Priyam Verghese, Andrew Creamer, Jennifer L. Dickson, Carolyn Horst, Helen Hall, Sophie Tisi, Monica Mullin, Tanya Patrick, John McCabe, Anne-Marie Hacker, Laura Farrelly, Esther Arthur-Darkwa, Neal Navani, Anand Devaraj, Allan Hackshaw, Arjun Nair, Sam M. Janes

  • July 4, 2026

Related Content

Lesion feature enhancement and boundary-aware fusion for pulmonary embolism recognition on CT images

Quantitative three-dimensional fracture mapping reveals subtype-specific morphology of acetabular roof column and wall fractures

Case Report: Clinical case of a giant plexiform neurofibroma of the liver in a patient with deletion of exon 1 of the NF1 gene